Organon stock jumps in premarket after MIUDELLA licensing deal, with 10-K filing in focus
Organon shares jumped 7.8% to $8.10 in premarket trading Monday after the company announced a global licensing deal for MIUDELLA, a hormone-free copper IUD from Sebela Pharmaceuticals. Organon agreed to pay $27.5 million upfront and up to $505 million in sales-based milestones, pending antitrust and FDA approvals. The company’s dividend record date is Monday, with payment set for March 12.
